Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
C/EBPβ overexpression increases SNCA expression in neuroblastoma cells and putative C/EBPβ and δ binding sites are present in the SNCA genomic region suggesting that these proteins could regulate SNCA transcription.
|
31209363 |
2020 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Misfolded α-synuclein causes hyperactive respiration without functional deficit in live neuroblastoma cells.
|
31848207 |
2020 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The conjugates were found to be have low cytotoxicity and reduced toxicity of α-Syn toward SH-SY5Y neuroblastoma cells.
|
30968030 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this purpose, we employed two cellular models; to induce severe ER stress, Mes23.5 cells were treated with 6-hydroxydopamine (6-OHDA) and for ER stress driven by chaperones, human neuroblastoma cells were stably transfected to overexpress familial mutants of α-synuclein (α-syn).
|
31100053 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This compound not only significantly inhibits the misfolding and aggregation of α-synuclein and protects neuroblastoma cells from α-synuclein toxicity, but also has a more specific binding site compared with positive controls.
|
31117342 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that fully differentiated human SH-SY5Y neuroblastoma cells grown in three-dimensional cell culture develop Lewy-body-like pathology upon exposure to exogenous α-synuclein species.
|
30926586 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicate that the uptake-mediated accumulation of αSyn in a human-derived neuroblastoma cell line triggered an adaptive response that involved proteins linked to ubiquitin ligases of the S-phase kinase-associated protein 1 (SKP1), cullin-1 (Cul1), and F-box domain-containing protein (SCF) family.
|
31167929 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have probed the mechanism of neurotoxicity of α-synuclein oligomers isolated in vitro using antibodies targeting the N-terminal region of the protein and found that the presence of the antibody resulted in a substantial reduction of the damage induced by the aggregates when incubated with primary cortical neurons and neuroblastoma cells.
|
31050886 |
2019 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Likewise, in human neuroblastoma SH-SY5Y cells exposed to low-dose MPP<sup>+</sup> , Nramp1 expression and cathepsin D activity were decreased, along with an increase in α-synuclein protein expression and aggregation.
|
29679389 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study we tested whether presence of human mutant GCase leads to accumulation and aggregation of α-synuclein in two models: in SHSY5Y neuroblastoma cells endogenously expressing α-synuclein and stably transfected with human GCase variants, and in Drosophila melanogaster co-expressing normal human α-synuclein and mutant human GCase.
|
30615125 |
2019 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Propanoylated lysine, a specific indicator of docosahexaenoic acid oxidation, was increased in neuronal differentiated human neuroblastoma SH-SY5Y cells overexpressing α-synuclein.
|
29892158 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we concluded that α-synuclein inhibited the starvation-induced autophagy in neuroblastoma SH-SY5Y cells via inhibiting the mTOR/Atg 5 signaling.
|
29551576 |
2018 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein.
|
29429047 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we have investigated the perturbations induced by low molecular weight α-synuclein and different types of α-synuclein oligomers in the neuroblastoma SH-SY5Y cells.
|
29539261 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy.
|
29974096 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study determined the impact of developmental Pb exposure on the α-Syn pathways in a mouse model knock-out (KO) for murine tau gene and in differentiated human neuroblastoma SHSY5Y cell line exposed to a series of Pb concentrations.
|
30068273 |
2018 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TH1-S31E associated with vesicular monoamine transporter 2 (VMAT2) and α-synuclein in neuroblastoma cells, and endogenous THSer(P)-31 was detected in VMAT2- and α-synuclein-immunoprecipitated mouse brain samples.
|
28637871 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Generated antibodies recognize misfolded hα-Syn produced by neuroblastoma cells, hα-Syn in the brain tissues of transgenic mouse strains and in the brain tissues of dementia with Lewy body cases.
|
28870518 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also show that squalamine almost completely suppresses the toxicity of α-synuclein oligomers in human neuroblastoma cells by inhibiting their interactions with lipid membranes.
|
28096355 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrate that α-synuclein exists as defined, subcellular-specific species that change characteristics in response to oxidative stress in neuroblastoma cells and in response to Parkinson's disease pathogenesis in human cerebellum and frontal cortex.
|
27837450 |
2017 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that recombinant expression of alpha-synuclein in human neuroblastoma cells enhances cellular levels of PLCβ1 but blunts its signaling pathway, preventing the agonist-dependent rise of cytoplasmic Ca<sup>2+</sup>.
|
27871937 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In support of these conclusions, mutations that target the region that promotes strong membrane interactions by α-synuclein oligomers suppressed their toxicity in neuroblastoma cells and primary cortical neurons.
|
29242346 |
2017 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, treatment of the hit compounds significantly reduced the α-synuclein expression in SH-SY5Y human neuroblastoma cells, that is implicated in Parkinson's disease.
|
28883518 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used neuroblastoma SH-SY5Y cell line and rat synaptoneurosomes treated with exogenous soluble ASN.
|
28516276 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, in this study we analysed the influence of these two proteins (α-Syn and wild-type or mutant Atx3) on modified redox signaling, a pathological process potentially linked to both diseases, and also the impact of exposure to iron and rotenone in SH-SY5Y neuroblastoma cells.
|
28236214 |
2017 |